<code id='4BC44509B9'></code><style id='4BC44509B9'></style>
    • <acronym id='4BC44509B9'></acronym>
      <center id='4BC44509B9'><center id='4BC44509B9'><tfoot id='4BC44509B9'></tfoot></center><abbr id='4BC44509B9'><dir id='4BC44509B9'><tfoot id='4BC44509B9'></tfoot><noframes id='4BC44509B9'>

    • <optgroup id='4BC44509B9'><strike id='4BC44509B9'><sup id='4BC44509B9'></sup></strike><code id='4BC44509B9'></code></optgroup>
        1. <b id='4BC44509B9'><label id='4BC44509B9'><select id='4BC44509B9'><dt id='4BC44509B9'><span id='4BC44509B9'></span></dt></select></label></b><u id='4BC44509B9'></u>
          <i id='4BC44509B9'><strike id='4BC44509B9'><tt id='4BC44509B9'><pre id='4BC44509B9'></pre></tt></strike></i>

          Home / entertainment / comprehensive

          comprehensive


          comprehensive

          author:comprehensive    Page View:67953

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In